BCL-2-INHIBITOREN
European patent · EP3788042 · In force
Register entry
- Publication number
- EP3788042
- Application number
- EP19797052
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Apr 29, 2019
- Published
- Mar 10, 2021
- Granted
- Feb 12, 2025
- Protection ends at the latest
- Apr 28, 2039
- Next annual fee due
- Apr 30, 2027
- IPC classes
- C07D 403/12 (2006.01)A61K 31/496 (2006.01)A61P 35/00 (2006.01)C07D 471/04 (2006.01)A61K 31/437 (2006.01)A61P 37/02 (2006.01)
- Priority
- WO PCT/CN2018/085217 29.04.2018WO PCT/CN2018/107134 21.09.2018
- PCT application
- PCT/CN2019/085001 29.04.2019
- PCT publication
- WO2019/210828 07.11.2019
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- May 1, 2026
Change
Published in Swissreg on 01.05.2026
- Dec 24, 2025
Change
Published in Swissreg on 24.12.2025
- Nov 27, 2025
Holder’s address changed
- Owner
- BeiGene Switzerland GmbH, Aeschengraben 27, 4051 Basel → BeOne Medicines I GmbH, Aeschengraben 27, 4051 Basel
Published in Swissreg on 27.11.2025
- May 1, 2025
Change
Published in Swissreg on 01.05.2025
- Feb 26, 2025
Agent entered
- Representative
- Murgitroyd & Company, Geneva Rhone 8 Sàrl, Rue du Commerce 4, 1204 Genève
Published in Swissreg on 26.02.2025
- Feb 12, 2025
Granted
- Specification status
- Non-published patent application → Granted patent
- Status of protective title
- Initiated → Active
Published in Swissreg on 12.02.2025
Parties
Inventor
XUE, Hai
Beijing 102206, CN
WANG, Zhiwei
Beijing 102206, CN
SUN, Hanzi
Beijing 102206, CN
GUO, Yunhang
Beijing 102206, CN
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.